PD20-08 TRENDS IN PROSTATE CANCER SPECIFIC MORTALITY BY RACE OVER TIME: A SEER ANALYSIS

Abstract

You have accessJournal of UrologyCME1 Apr 2023PD20-08 TRENDS IN PROSTATE CANCER SPECIFIC MORTALITY BY RACE OVER TIME: A SEER ANALYSIS Davuluri Meenakshi, Gina Demeo, Himanshu Nagar, Leonardo Borregales, and Jim Hu Davuluri MeenakshiDavuluri Meenakshi More articles by this author , Gina DemeoGina Demeo More articles by this author , Himanshu NagarHimanshu Nagar More articles by this author , Leonardo BorregalesLeonardo Borregales More articles by this author , and Jim HuJim Hu More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003286.08AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: It has been demonstrated there was an increase in metastatic prostate cancer diagnosis from 2004 to 2013 in a previous SEER analysis. Our goal was to evaluate trends in prostate cancer specific mortality (PCSM) during this time period to determine if increased metastatic disease correlated with increased mortality rates. METHODS: Using Surveillance, Epidemiology, and End Results (SEER) registry database, we identified men diagnosed with prostate cancer from 2004-2013. Men were stratified by age at diagnosis, race (White, Black, Hispanic, Asian, Native American, and Other), and stage at diagnosis. Number of deaths were identified and PCSM mortality was calculated. Descriptive statistics were used. RESULTS: We identified 497,166 men in SEER who met our inclusion criteria from 2004-2013. In this time period, the overall cohort PCSM decreased from 9.65% in 2004 to 5.95% in 2013 (Figure 1). We then stratified PCSM by race (Figure 2). We found that across all races PCSM decreased from 2004 to 2013 with the largest decrease in Native American men (18.0% to 10.4%) followed by Black men (11.6% to 7.0%). We further sub-stratified PCSM for men with distant metastasis at time of diagnosis (Figure 3). In this cohort of men, again a decrease in PCSM across all races was seen. The differences in PCSM from 2004 to 2013 are 3.9%, 8.9%, 5.9%, 13.2% and 22.8% for White, Black, Hispanic, Asian, and Native American men respectively. The largest decrease of PCSM was seen in Native American men with a 22% reduction of death rates in men diagnosed with metastatic disease from 2004 to 2013. CONCLUSIONS: PCSM has decreased overtime despite previous findings of increasing metastatic disease at time of diagnosis. This may be due to improved treatment options for metastatic disease. PCSM has decreased across all races, however Native American and Black men continue to have higher rates PCSM compared to other races. As more interventions are implemented to address disparities, longitudinal studies will be required to determine the impacts on survival outcomes. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e586 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Davuluri Meenakshi More articles by this author Gina Demeo More articles by this author Himanshu Nagar More articles by this author Leonardo Borregales More articles by this author Jim Hu More articles by this author Expand All Advertisement PDF downloadLoading ...